Prograf

Prograf contains the active ingredient tacrolimus, a potent immunosuppressant manufactured by Astellas Pharma. First approved by the FDA in 1994, tacrolimus has become one of the most widely used anti-rejection medications worldwide and is considered a cornerstone of modern transplant medicine. Prograf is always used in combination with other immunosuppressants such as corticosteroids and mycophenolate to protect transplanted organs from the body’s immune response.

How Prograf Works

Tacrolimus belongs to a class of drugs called calcineurin inhibitors. It works by blocking the activity of calcineurin, a protein found inside T-lymphocytes (a type of white blood cell). Under normal circumstances, calcineurin activates T-cells to produce substances called lymphokines which trigger the immune system to attack foreign tissue. By inhibiting this process, Prograf effectively suppresses the immune response that would otherwise cause the body to reject a transplanted organ. This mechanism is similar to ciclosporin (cyclosporine), another calcineurin inhibitor, though clinical studies have shown tacrolimus to be more potent on a milligram-per-milligram basis. Patients managing other aspects of their post-transplant health may also explore our heart health medications section.

Clinical Effectiveness

Prograf’s efficacy in preventing organ rejection has been established through multiple randomized controlled trials in kidney, liver, and heart transplant recipients. In kidney transplant studies, tacrolimus-based regimens demonstrated lower rates of acute rejection compared to cyclosporine-based protocols.

In two major liver transplant trials — one conducted in the United States and one in Europe — tacrolimus combined with corticosteroids showed favorable outcomes in both adult and pediatric patients. For heart transplant patients, clinical data similarly supports tacrolimus as an effective foundation for immunosuppressive therapy. More recently, Prograf has also received FDA approval for use in lung transplant recipients. Patients who are also managing conditions related to their transplant, such as new-onset diabetes, should work closely with their transplant team to balance treatment goals.

Dosing Guidelines

Prograf dosing is highly individualized and depends on the type of organ transplanted, time since transplant, concurrent medications, and the patient’s blood levels of tacrolimus. For kidney transplant patients, the typical initial oral dose is 0.2 mg/kg/day divided into two doses taken every 12 hours. For liver transplant patients, the recommended starting dose is 0.10 to 0.15 mg/kg/day, also divided into two doses. Heart transplant patients usually start at 0.075 mg/kg/day in two divided doses. Lung transplant recipients may require similar dosing, though patients with cystic fibrosis often need higher doses due to reduced bioavailability of oral tacrolimus.

Capsules should be taken consistently either with or without food — but the same approach should be used each time because food can affect how much tacrolimus the body absorbs. Grapefruit and grapefruit juice must be avoided as they can significantly increase tacrolimus blood levels. Therapeutic drug monitoring through regular blood tests is required throughout treatment, and doses are adjusted based on trough concentrations to maintain effective immunosuppression while minimizing toxicity.

Who Should Not Take Prograf

Prograf is contraindicated in patients with a known hypersensitivity to tacrolimus. The injectable formulation is also contraindicated in patients allergic to HCO-60 (polyoxyl 60 hydrogenated castor oil). Tacrolimus should not be used simultaneously with cyclosporine — if switching between the two drugs, at least 24 hours must pass after discontinuing one before starting the other. Patients with pre-existing kidney impairment should receive doses at the lower end of the recommended range due to tacrolimus’s potential for nephrotoxicity.

The medication should be prescribed only by physicians experienced in immunosuppressive therapy, and patients should be managed at facilities with adequate laboratory and medical resources. Patients taking Imuran (azathioprine) or other immunosuppressants as part of their regimen should have all medications carefully coordinated by their transplant team.

Comparing Prograf to Other Immunosuppressants

Prograf is frequently compared to cyclosporine, the other major calcineurin inhibitor used in transplant medicine. While both drugs work through a similar mechanism, tacrolimus has generally shown superior efficacy in preventing acute rejection episodes across organ types. However, the side effect profiles differ — tacrolimus is more commonly associated with new-onset diabetes and neurotoxicity, while cyclosporine tends to cause more cosmetic side effects like gum overgrowth and excessive hair growth. Other immunosuppressive medications used alongside Prograf include Plaquenil for autoimmune conditions and Copaxone for immune modulation in different clinical contexts. Our blog on prediabetes and type 2 diabetes may also be helpful for transplant patients monitoring their metabolic health.

Storage and Handling

Store Prograf capsules at room temperature (77°F / 25°C), with excursions permitted between 59°F and 86°F (15°C to 30°C). Keep capsules in the original aluminum packaging and protect them from moisture and light. Tacrolimus can cause harm to a developing fetus, so appropriate handling precautions should be followed.

Buying Prograf Online

If you’re looking to buy Prograf online or order medication online at a lower price, licensed international pharmacies can provide significant savings. At our online pharmacy, Prograf is available in 0.5 mg, 1 mg, and 5 mg capsules from the original Astellas manufacturer. All orders over $150 ship free, and medications are sourced exclusively from licensed dispensaries.